FULC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Fulcrum Therapeutics Inc (FULC) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company's promising clinical data and analyst optimism suggest potential upside, the recent price decline, lack of strong technical signals, and financial challenges indicate that waiting for further clarity on its development pipeline and financial performance may be prudent.
The stock is currently trading at $8.73, with a pre-market decline of -2.78%. The MACD histogram is negative and expanding, indicating bearish momentum. RSI is at 28.28, suggesting the stock is nearing oversold territory but not yet providing a clear buy signal. Moving averages are converging, and the stock is trading near its S1 support level of 8.807, with resistance levels at 10.22 and 11.633.
Encouraging clinical data from the Phase 1b PIONEER study for pociredir, showing significant HbF induction and favorable tolerability.
Analysts maintain strong Buy ratings with price targets ranging from $17 to $25, indicating potential upside.
The company has a strong cash position of $352.3 million to support its R&D and operational needs.
Recent stock price decline of -2.78% in both pre-market and regular trading.
Financial performance remains weak, with negative net income (-$20.33M) and EPS (-$0.
despite slight YoY improvements.
The announcement of a $175M public offering may dilute shareholder value.
Lack of significant hedge fund or insider trading activity and no recent congress trading data.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of -$20.33M, although net income improved by 22.73% YoY. EPS increased by 14.81% YoY to -$0.31. Gross margin dropped to 0, indicating no profitability.
Analysts are optimistic about Fulcrum Therapeutics, maintaining Buy ratings with price targets ranging from $17 to $25. They view the clinical data as encouraging and supportive of advancing pociredir toward a potential registrational trial in 2026. However, one analyst lowered the price target slightly from $18 to $17, reflecting some caution.
